Differential effect of PMS777, a new type of acetylcholinesterase inhibitor, and galanthamine on oxidative injury induced in human neuroblastoma SK-N-SH cells

被引:19
作者
Ezoulin, MJM
Li, J
Wu, GR
Dong, CZ
Ombetta, JE
Chen, HZ
Massicot, F
Heymans, F
机构
[1] Univ Paris 05, Fac Sci Pharmaceut & Biol, Toxicol Lab, F-75270 Paris, France
[2] Univ Paris 07, Unite Pharmacochim Mol & Syst Membranaires EA2381, F-75251 Paris, France
[3] Univ Med 2, Dept Pharmacol, Shanghai 200025, Peoples R China
[4] Univ Med Xinjian, Coll Pharm, Urumqi 830054, Xinjang, Peoples R China
关键词
acetylcholinesterase inhibitor; tetrahydrofuran derivatives; galanthamine; SK-N-SH cells; oxidative stress;
D O I
10.1016/j.neulet.2005.07.026
中图分类号
Q189 [神经科学];
学科分类号
071006 ;
摘要
in the search for highly selective and potent cholinesterase inhibitors (AChEI) being able to improve oxidative injury, PMS777, a tetrahydrofuran derivative, was designed as a novel dual PAF and acetylcholinesterase inhibitor. The aim of this study was to investigate the modulatory effects of PMS777 and galanthamine, another AChEI, on the oxidative injury induced in neuronal cells. The SK-N-SH cells stimulated with LPS + IL-(1 beta) were selected to investigate the direct inhibitory effect of PMS777 and galanthamine. LPS + IL-(1 beta) induced oxidative injury as assessed by ROS production (29%), GSH depletion (11%) and loss of mitochondrial activity (22%). GSH depletion was never decreased by either drug. In contrast, ROS production and mitochondrial activity were totally prevented by addition of PMS777 but not galanthamine. PMS777 also inhibits butylcholinesterase and it shows selectivity for acetylcholinesterase. Thus, this PAF antagonist inaugurates a new type of AChEI, able to fight oxidative injury. Therefore, PMS777 could be of interest on patients with cognitive impairments and inflammatory damage, as in AD. (C) 2005 Elsevier Ireland Ltd. All rights reserved.
引用
收藏
页码:61 / 65
页数:5
相关论文
共 33 条
[11]   Binding of platelet-activating factor to platelets of Alzheimer's disease and multiinfarct dementia patients [J].
Hershkowitz, M ;
Adunsky, A .
NEUROBIOLOGY OF AGING, 1996, 17 (06) :865-868
[12]   Comparison studies of cholinesterase inhibitors for Alzheimer's disease [J].
Hogan, DB ;
Goldlist, B ;
Naglie, G ;
Patterson, C .
LANCET NEUROLOGY, 2004, 3 (10) :622-626
[13]   Progress in clinical neurosciences: Treatment of Alzheimer's disease and other dementias - Review and comparison of the cholinesterase inhibitors [J].
Hogan, DB ;
Patterson, C .
CANADIAN JOURNAL OF NEUROLOGICAL SCIENCES, 2002, 29 (04) :306-314
[14]   Interleukin-1β induced cyclooxygenase 2 expression and prostaglandin E2 secretion by human neuroblastoma cells:: implications for Alzheimer's disease [J].
Hoozemans, JJM ;
Veerhuis, R ;
Janssen, I ;
Rozemuller, AJM ;
Eikelenboom, P .
EXPERIMENTAL GERONTOLOGY, 2001, 36 (03) :559-570
[15]  
Inglis F, 2002, INT J CLIN PRACT, P45
[16]   Have cholinergic therapies reached their clinical boundary in Alzheimer's disease? [J].
Jones, RW .
INTERNATIONAL JOURNAL OF GERIATRIC PSYCHIATRY, 2003, 18 :S7-S13
[17]   Interactions between Alzheimer's disease and cerebral ischemia-focus on inflammation [J].
Koistinaho, M ;
Koistinaho, J .
BRAIN RESEARCH REVIEWS, 2005, 48 (02) :240-250
[18]  
LeTexier L, 1996, J LIPID MEDIAT CELL, V13, P207
[19]  
LeTexier L, 1996, J LIPID MEDIAT CELL, V13, P189
[20]   The metabolism and excretion of galantamine in rats, dogs, and humans [J].
Mannens, GSJ ;
Snel, CAW ;
Hendrickx, J ;
Verhaeghe, T ;
Le Jeune, L ;
Bode, W ;
van Beijsterveldt, L ;
Lavrijsen, K ;
Leempoels, J ;
Van Osselaer, N ;
Van Peer, A ;
Meuldermans, W .
DRUG METABOLISM AND DISPOSITION, 2002, 30 (05) :553-563